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Summary
Background.— The distribution of left ventricular ejection fraction (LVEF) —a key factor in
coronary artery disease (CAD) patient management and prognostication— is poorly documented.Angina;
Left ventricular
ejection fraction;
Heart rate
Objective.— To determine LVEF and heart rate (HR) values, and describe the management of
stable CAD patients in France.
Methods.— The INDYCE survey was a prospective, multicentre registry of consecutive stable
CAD outpatients attending a cardiology consultation. The survey focused on LVEF values mea-
sured using the echocardiographic Simpson biplane method. Drug therapy, resting HR, blood
pressure and symptoms were also recorded.
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Results.— Overall, 3119 patients (68.4± 11.0 years; 80% men) were enrolled. LVEF was
56.1± 11.8% on average, and was poor (< 40%) and moderately impaired (40—50%) in 9.6%
(n = 298) and 19.8% (n = 619) of cases, respectively. Symptomatic angina pectoris was present
in 19.2% of cases and only 40.6% of patients were asymptomatic (no angina and NYHA class≤ I)
despite relatively aggressive management (79.0% of patients had undergone coronary angio-
plasty and/or bypass graft). Interestingly, 14.1% of patients with LVEF less than 40% were
asymptomatic. In multivariable analysis, LVEF less than 40% was associated most strongly with
symptomatic status (odds ratio 3.82; 95% CI 2.59—5.63; P < 0.0001), together with female sex,
age greater than 75 years, diabetes, HR greater or equal to 70 bpm, sedentariness, obesity and
disease duration.
Conclusion.— Only 9.6% of stable CAD patients had severe left ventricular dysfunction; among
them, 14.1% were strictly asymptomatic. This could justify regular LVEF measurement in CAD
patients. Three potentially reversible factors (HR≥ 70 bpm, being overweight and sedentari-
ness) were linked independently to the presence of symptoms.
© 2010 Elsevier Masson SAS. All rights reserved.
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Résumé
État des lieux.— La prise en charge et l’évaluation du pronostic des patients coronariens stables
sont en grande partie basées sur la fraction d’éjection ventriculaire gauche (FEVG), mais la
distribution de celle-ci chez ces patients est peu documentée.
Objectifs.— Décrire la distribution des valeurs de FEVG et de fréquence cardiaque de repos
(Fc) ainsi que la prise en charge des patients coronariens stables en France.
Méthodes.— Le registre INDYCE multicentrique et prospectif a inclus consécutivement les
patients coronariens stables vus en consultation externe de cardiologie. L’objectif principal
était la mesure de la FEVG par la méthode de Simpson Biplan. Le traitement, la Fc, la pression
artérielle et la symptomatologie étaient aussi analysés.
Résultats.— Au total, 3119 patients (âge moyen : 68,4± 11,0 ans ; 80 % d’hommes) ont été
inclus. La FEVG était de 56,1± 11,8 % ; la fonction systolique ventriculaire gauche était sévère-
ment (FEVG< 40%) ou modérément (40—50%) altérée chez respectivement 9,6 % (n = 298) et
19,8 % (n = 619) des patients. Le pourcentage de patients qui souffraient d’angor était de 19,2 %
et seulement 40,6 % d’entre eux étaient strictement asymptomatiques (pas d’angor et classe
NYHA≤ 1) malgré une prise en charge assez agressive (79,0 % des patients ayant bénéﬁcié d’au
moins une procédure de revascularisation). On note que 14,1 % des patients avec une FEVG
inférieure à 40% étaient asymptomatiques. En analyse multivariée, l’existence d’une FEVG
inférieure à 40% était le facteur le plus fortement associé à l’existence de symptômes (OR
3,82 ; IC 95% : 2,59 à 5,63 ; p < 0,0001), les autres paramètres étant le sexe féminin, l’âge
supérieur à 75 ans, le diabète, une Fc supérieure ou égale à 70 bpm, la sédentarité, l’obésité
et l’ancienneté de la maladie angineuse.
Conclusion.— Le pourcentage de patients coronariens stables présentant une dysfonction ven-
triculaire gauche sévère est de 9,6% ; parmi eux, 14,1 % sont strictement asymptomatiques,
ce qui pourrait justiﬁer une mesure régulière de la FEVG chez l’ensemble des coronariens.
Seulement trois facteurs potentiellement réversibles (obésité, sédentarité et Fc≥ 70 bpm) sont
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Abbreviations
bpm beats per minute
CAD coronary artery disease
HR heart rate
LVEF left ventricular ejection fraction
NYHA New York Heart Association
OR odds ratioBackground
Discovery of systolic left ventricular dysfunction is a key
event in the course of stable coronary artery disease (CAD).
—
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ndeed, it worsens the prognosis [1,2] and often requires
hanges in patient management, including escalation of
edical therapy and reassessment of the need for revas-
ularization.
As systolic left ventricular dysfunction is asymptomatic
n 50—65% of cases [3,4], especially when only moderate,
here is a strong likelihood that the myocardial impairment
ill only be diagnosed when already severe and irreversible
5]. The prevalence of systolic left ventricular dysfunction
especially that of moderate forms in patients with sta-
le CAD— is poorly known. Most data come from the Euro
eart Survey [6,7], in which left ventricular ejection frac-
ion (LVEF) was greater than 50% in 66% of CAD patients,
etween 40% and 50% in 23% of CAD patients, and less than
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0% in 11% of CAD patients. However, these data must be
nterpreted with care, as LVEF was measured in only two-
hird of the study population. In addition, the prevalence
f symptoms in CAD patients receiving the most modern
reatments is poorly documented.
The main objective of the INDYCE (insufﬁsance coron-
ire stable, dysfonction ventriculaire gauche et fréquence
ardiaque) registry was to evaluate systolic left ventricular
unction prospectively in a large population of patients with
table CAD. Secondary objectives were to examine patient
anagement, symptoms and heart rate (HR) distribution.
ethods
his prospective, cross-sectional, epidemiological survey
as conducted in France. As it was an observational
tudy, it entailed no change in standard patient man-
gement. In keeping with French law, all data were
ollected anonymously and the data ﬁle was declared to
he French computer watchdog body (Commission nationale
e l’informatique et des libertés). The patients were given
ritten information on the nature and aims of the study.
atients
he study population consisted exclusively of ambula-
ory patients seen at a hospital or private cardiology
onsultation. Between 15 June and 31October 2008, each
nvestigator was asked to recruit prospectively a maximum
f 10 consecutive patients with stable CAD.
Patients were eligible if they were greater or equal to
8 years of age and had documented CAD (history of coro-
ary revascularization and/or coronary angiography showing
1 stenosis > 60%), and/or a history of myocardial infarction
r an acute coronary syndrome, and/or clinical angina and
positive ischaemia test (with the exception of an conven-
ional exercise test in women).
Stable CAD was deﬁned by the absence of acute coronary
vents and myocardial revascularization during the 6months
efore inclusion.
ata collection
chocardiography
VEF was measured using the Simpson biplane method [8,9].
n illustrated technical ﬁle describing the technique pre-
isely was provided to each investigator.
linical data
he monthly number of angina attacks was recorded, and
yspnoea was scored using the New York Heart Association
NYHA) classiﬁcation. Blood pressure and HR were measured
fter a 5-minute rest in the supine position; HR was mea-
ured from the pulse.tatistical analysis
ontinuous variables are expressed as means± standard
eviations and categorical variables as percentages. Propor-
ions were compared between groups using the Khi2 test.
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verall comparisons between LVEF groups were performed
sing a one-way analysis of variance model for continuous
ariables and a Khi2 test or Fisher’s exact test for categorical
ariables.
Baseline characteristics were tabulated according to
hree prespeciﬁed ejection fraction strata (< 40%, 40—50%,
nd > 50%), as used in the ECHOES study [3]. As recent data
uggest that HR greater or equal to 70 beats per minute
bpm) has a strong prognostic inﬂuence on coronary events
10,11], HR values were dichotomized at 70 bpm.
Factors correlating with symptomatic status (i.e. angina
ttacks and/or NYHA class > I) were identiﬁed using univari-
te and multivariable logistic regression models. Factors
hat were signiﬁcant (˛ ≤ 0.05) in the univariate analysis
ere included in the multivariable model, using a stepwise
rocedure with an entry threshold of 0.10 and an exit thresh-
ld of 0.05.
esults
etween June and November 2008, 3193 patients with sta-
le CAD were enrolled consecutively. Seventy-four patients
2.3%) were excluded, because of missing data (n = 5), non-
istribution of written information (n = 4) or non-respect
f inclusion criteria (n = 65). This analysis focuses on the
emaining 3119 patients.
ecruiting centres
mong 979 cardiologists selected by the National Collegiate
f French Cardiologists, 554 agreed to participate in the
tudy and 343 actually participated. The demographic char-
cteristics of the cardiologists were similar to those of the
121 cardiologists practising in France in 2007, based on data
rom Direction de la récherche des études et de l’évaluation
tatistique and Observatoire national de la démographie des
rofessions de santé [12].
atients
able 1 shows the patients’ general characteristics. Most
f the patients were men (80.3%). The mean age was
8± 11 years. Risk factors and comorbidities occurred fre-
uently: nearly one-quarter of the patients were diabetic,
1.6% were hypertensive, 18.6% were active smokers; two-
hird were overweight and 28.5% also had extracoronary
rterial disease.
The mean CAD duration was 7.6± 6.5 years and was
requently severe: 44.5% of the patients had a history
f myocardial infarction, 79.0% had been revascularized
angioplasty 61.9%, bypass grafting 24.5%) and 15.2% had
een hospitalized at least once for heart failure.
eft ventricular ejection fraction distributionhe distribution of LVEF values is shown in Table 1 and
ig. 1. Mean LVEF was 56.1± 11.8%, and was greater than
0% in 70.6% of patients (n = 2202), 40—50% in 19.8% of
atients (n = 619), and less than 40% in 9.6% of patients
n = 298).
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Table 1 Coronary artery disease risk factors, comorbidity and severity of the disease.
Total population
(n = 3119)
LVEF > 50%
(n = 2202)
LVEF 40—50%
(n = 619)
LVEF < 40%
(n = 298)
P
Age (years) 68.4± 11.0 67.8± 10.9 69.5± 11.0 70.5± 11.7 < 0.0001
Men 80.3 79.4 84.2 78.2 0.021
Insulin-dependent diabetes 5.6 4.5 6.5 11.5 < 0.0001
Non-insulin-dependent diabetes 18.7 17.7 22.3 18.6 0.037
Hyperlipidaemia 81.8 81.5 83.7 80.4 0.369
High blood pressure 61.6 63.4 59.4 53.4 0.002
Familial coronary artery disease 25.0 25.4 23.6 24.8 0.671
Current smoking 18.6 18.6 18.1 19.5 0.882
Peripheral vascular disease 28.5 26.4 31.7 37.5 < 0.0001
Sedentariness 57.4 54.3 62.7 68.8 < 0.0001
Asthma 3.9 3.9 3.2 5.6 0.229
COPD 9.5 8.4 9.5 17.6 < 0.0001
Chronic renal failure 13.9 10.2 18.0 33.3 < 0.0001
Depression 21.4 20.2 21.2 30.1 < 0.001
Body mass index 26.9± 4.0 26.9± 3.9 27.1± 3.9 26.4± 4.4 0.037
Duration of coronary artery
disease (years)
7.6± 6.5 6.9± 5.9 8.7± 7.2 10.4± 8.1 < 0.0001
Prior myocardial infarction 44.5 35.4 63.7 72.2 < 0.0001
Resting heart rate 64.5± 10.4 64.0± 10.1 65.3± 10.7 66.2± 11.5 < 0.001
Heart rate≥ 70 beats per minute 30.1 27.9 33.5 38.6 < 0.001
Systolic blood pressure (mmHg) 131.8± 15.4 132.9± 14.9 130.7± 15.5 125.4± 16.3 < 0.0001
Diastolic blood pressure (mmHg) 75.8± 8.4 76.2± 8.2 75.1± 8.4 73.9± 9.1 < 0.0001
Sinus rhythm 90.1 92.3 86.6 80.8 < 0.0001
LVEF (%) 56.1± 11.8 62.2± 6.9 45.9± 3.4 32.3± 5.9 < 0.0001
Left atrium area (cm2) 20.4± 6.0 19.6± 5.4 21.8± 6.9 23.8± 6.7 < 0.0001
NYHA class < 0.001
0 or I 43.6 50.8 31.9 14.8
II 46.9 44.0 54.0 53.4
III or IV 9.6 5.3 14.2 31.9
Angina (≥ 1 crisis/month) 19.2 16.7 23.6 29.7 < 0.001
Asymptomatic patients (NYHA
class 0 or I and no angina)
40.6 47.3 29.4 14.1 < 0.001
Prior hospitalization for heart
failure
15.2 6.7 24.8 58.7 < 0.0001
Data are mean± standard deviation or percentage. COPD: chronic obstructive pulmonary disease; LVEF: left ventricular ejection fraction;
NYHA: New York Heart Association.
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analysis was used to determine if demographic factors
(age, sex), clinical characteristics (diabetes, smoking,
family history of CAD, lipid disorders, obesity, systolic pres-
sure, HR, prior myocardial infarction, disease duration),
treatments (history of bypass grafting or angioplasty) and
symptomatic status of the patients were linked indepen-
dently to LVEF less than 40%. Finally, age greater than
75 years (odds ratio [OR] 1.36), HR greater or equal to
70 bpm (OR 1.53), disease duration greater or equal to
6 years (OR 1.57), previous myocardial infarction (OR
2.96), absence of myocardial revascularization (OR 1.56),
high blood pressure (OR 0.60), and presence of symptoms
(angina and/or NYHA class > I) (OR 3.76) were linked
independently with severe left ventricular dysfunction
(Table 2 ).
S
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peart rate distribution
he mean resting HR was 64.5± 10.4 bpm (Table 1 and
ig. 2). The mean HR in the 74.6% of patients who were
aking beta-blockers was 63.3± 9.9 bpm, compared with
8.0± 10.9 bpm in the other patients (P < 0.0001). HR was
reater or equal to 70 bpm in 30.1% of patients overall, and
n 25.4% and 43.7% of patients taking and not taking beta-
lockers, respectively. HR-lowering calcium antagonists
ere prescribed to only 9.0% of the patients overall, and to
2.2% of the patients who were not taking a beta-blocker.ymptoms
verall, 19.2% of patients had at least one angina attack
er month; 40.6% of patients were considered completely
358 J.-Y. Tabet et al.
F
a
e
a
a
(
f
t
eigure 1. Left ventricular ejection fraction (LVEF) distribution.
symptomatic (NYHA class 0 or I, and no angina). Inter-
stingly, 14.1% of patients with LVEF less than 40% were
symptomatic.
Univariate regression analysis followed by multivari-
ble analysis was used to identify demographic factors
age, sex), clinical characteristics (diabetes, smoking,
amily history of CAD, lipid disorders, obesity, sys-
m
w
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Table 2 Factors linked to the presence of a left ventricular e
Criteria U

Age > 75 years 1
Body mass index≥ 30
Heart rate≥ 70 1
Male sex
Sedentariness 1
Disease duration≥ 6 years 3
Diabetes
Previous myocardial infarction 9
Previous revascularization 1
Current smoking
Family history of coronary artery disease
Dyslipidaemia
High blood pressure 5
Beta-blocker therapy
Calcium antagonist therapy 1
Symptomatic (NYHA class > I and no angina) 7
ACEI or ARB therapy 2
Anti-ischaemic therapy (nitrates, nicorandil, trimetazidine) 1
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin rec
Association.olic pressure, HR, prior myocardial infarction, dis-
ase duration), paraclinical variables (LVEF) and treat-
ents (history of bypass grafting or angioplasty) that
ere linked independently to the presence of symp-
oms.
Age greater than 75 years (OR 2.52), female sex (OR
.44), obesity (body mass index≥ 30) (OR 1.50), diabetes
jection fraction less than 40%.
nivariate analysis Multivariable analysis
2 P P Odds ratio (95% CI)
9 < 0.0001 0.03 1.36 (1.02—1.80)
0.8 0.3
1 < 0.001 0.003 1.53 (1.15—2.03)
0.8 0.36
7 < 0.0001 0.25 1.18 (0.88—1.57)
5 < 0.0001 0.002 1.57 (1.18—2.09)
5.5 0.02 0.57 1.09 (0.80—1.48)
3 < 0.0001 < 0.0001 2.96 (2.20—3.99)
4 0.002 0.001 0.64 (0.49—0.84)
0.2 0.6
0.01 0.9
0.3 0.5
6 < 0.0001 < 0.001 0.60 (0.45—0.80)
5.8 0.02 0.9 1.02 (0.71—1.45)
4.5 0.001 < 0.0001 0.25 (0.16—0.40)
2 < 0.0001 < 0.0001 3.76 (2.55—5.55)
7 < 0.0001 < 0.0001 3.80 (2.45—5.90)
6.3 0.009 0.06 1.36 (0.98—1.87)
eptor blocker; CI: conﬁdence interval; NYHA: New York Heart
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Table 3 Factors linked to the presence of symptoms (angina and/or New York Heart Association class > I).
Criteria Univariate analysis Multivariable analysis
2 P P Odds ratio (95% CI)
Age > 75 years 146 < 0.0001 < 0.0001 2.52 (2.05—3.09)
Body mass index≥ 30 29 < 0.0001 < 0.001 1.50 (1.20—1.87)
Heart rate≥ 70 25 < 0.0001 0.02 1.25 (1.03—1.51)
Female sex 42 < 0.0001 0.001 1.44 (1.14—1.81)
Sedentariness 158 < 0.0001 < 0.0001 2.14 (1.81—2.55)
LVEF < 40% 72 < 0.0001 < 0.0001 3.82 (2.59—5.63)
Disease duration≥ 6 years 30 < 0.0001 0.006 1.28 (1.07—1.52)
Diabetes 43 < 0.0001 < 0.001 1.47 (1.19—1.82)
Previous myocardial infarction 1.2 0.33
Previous revascularization 2.8 0.01 0.09 0.86 (0.72—1.02)
Current smoking 5.4 0.02 0.75 0.99 (0.81—1.22)
Family history of coronary artery
disease
1.9 0.1
Dyslipidaemia 1.4 0.2
High blood pressure 15 0.02 0.07 1.03 (0.99—1.06)
Beta-blocker therapy 4.5 0.03 0.006 1.32 (1.08—1.60)
Calcium antagonist therapy 3.2 0.053
ACEI or ARBS therapy 16.3 < 0.0001 0.028 1.24 (1.02—1.50)
Anti-ischaemic therapy (nitrates,
nicorandil, trimetazidine)
37 < 0.0001 < 0.0001 1.96 (1.55—2.49)
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CI: conﬁdence interval; LVEF: left ventricular ejection
fraction; NYHA: New York Heart Association.
(OR 1.47), HR greater or equal to 70 bpm (OR 1.25), seden-
tariness (OR 2.14), disease duration greater than 6 years (OR
1.28) and LVEF less than 40% (OR 3.82) were associated inde-
pendently with symptomatic status (Table 3).
Management
Patient management (Table 4) was relatively aggressive
(91.5% of patients had a history of coronary angiogra-
phy and 79.0% had undergone coronary bypass grafting
and/or coronary angioplasty). Drug therapy was largely in
keeping with contemporary guidelines: 91.0% of patients
were receiving antiplatelet therapy, 85.9% a statin, 71.5%
an angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker, and 74.6% a beta-blocker. Only 44.7% of
Figure 2. Heart rate distribution. Heart rate was greater or equal
to 70 bpm in 30% of patients overall, in 25.4% of patients on beta-
blockers and in 43.7% of patients not on beta-blockers. bpm: beats
per minute.
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tatients were receiving a combination of a beta-blocker,
statin, an angiotensin-converting enzyme inhibitor or
ngiotensin receptor blocker, and an antiplatelet drug, while
9.8% of patients were receiving all these treatments and
ad well-controlled blood pressure (systolic < 140mmHg and
iastolic < 90mmHg). Only 23% of patients were receiv-
ng the combination of the above four drugs and had
ell-controlled blood pressure and an HR less than
0 bpm.
A total of 9.9% of patients were not receiving any
ntiangina drug therapy (beta-blockers, calcium antago-
ists, nitrate derivatives and related drugs, trimetazidine or
vabradine), while 61.8%, 23.1%, 4.6% and 0.6% of patients
ere receiving one, two, three or four antiangina drugs,
espectively.
iscussion
n some respects, patients with stable CAD are poorly char-
cterized. Large clinical studies of such patients [10,13—18],
esigned to validate speciﬁc treatments or management
trategies, have been useful, but the study populations were
ot representative of patients seen in routine practice: for
xample, patients with left ventricular dysfunction were
xcluded from the PEACE study [14], while patients with
ormal left ventricular function were excluded from the
EAUTIFUL study [15].
Some large registries, such as the Euro Heart Survey [6,7]
nd the French ELAN study [19], provide a more compre-
ensive picture of the clinical features and management of
hese patients, but their results are incomplete. In partic-
360 J.-Y. Tabet et al.
Table 4 Management and medical therapy.
Total
population
(n = 3119)
LVEF > 50%
(n = 2202)
LVEF 40—50%
(n = 619)
LVEF < 40%
(n = 298)
P
Prior coronary angiography 91.5 92.3 89.8 88.9 0.035
Prior PCI 61.9 65.2 55.7 51.0 < 0.0001
Prior CABG 24.5 23.1 26.7 29.9 0.014
Antiplatelet agent 91.0 93.4 89.0 77.5 < 0.001
Aspirin 54.5 53.9 57.5 52.0 0.51
Clopidogrel 23.6 24.1 21.2 24.7 0.51
Aspirin + clopidogrel 22.0 22.0 21.2 23.4 0.51
VKA 10.8 7.5 13.9 28.9 < 0.001
Statin 85.9 87.3 84.0 79.5 < 0.001
Other lipid-lowering agent 8.1 8.2 8.2 6.7 0.67
ACEI 49.3 43.5 60.7 67.8 < 0.001
ARB 23.5 23.0 24.6 25.2 0.57
ACEI and/or ARB 71.5 65.1 84.1 91.9 < 0.01
Beta-blocker 74.6 72.8 78.4 80.5
> 125% of target dose 3.2 3.4 3.1 2.1
75—125% of target dose 35.8 37.0 23.2 35.4
50—75% of target dose 36.7 39.1 33.4 27.5
25—50% of target dose 18.4 15.6 24.3 25.4
< 25% of target dose 5.8 4.9 7.0 9.6
Mean dose (% of target dose) 67.1± 46.8 69.6± 49.8 62.6± 40.0 59.7± 36.8 < 0.001
Nitrate 7.6 6.9 7.8 12.8 0.001
Nicorandil 8.5 9.1 7.0 7.4 0.174
Trimetazidine 5.0 5.0 4.2 7.1 0.180
Dihydropyridine 19.4 21.9 16.6 6.7 < 0.001
Non-dihydropyridine calcium
antagonist
9.0 10.6 6.5 2.4 < 0.001
Beta-blocker + AA +ACEI/ARB +
statin
44.7 41.5 53.3 50.3 < 0.001
Data are mean± standard deviation or percentage. The beta-blocker dose is expressed as a percentage of the target dose (bisoprolol,
10mg; acebutolol, 400mg; atenolol, 100mg; celiprolol, 400mg; metoprolol, 200mg) [25]. AA: antiplatelet agent; ACEI: angiotensin-
converting enzyme inhibitor; ARB: angiotensin receptor blocker; CABG: coronary artery bypass graft; PCI: percutaneous coronary
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Hintervention; VKA: vitamin K antagonist.
lar, we are not aware of any studies focusing on systolic
eft ventricular function in patients with stable CAD, even
hough this is the most potent prognostic factor [20]. Fur-
hermore, the prognostic signiﬁcance of HR (especially for
oronary events), with a cut-off of 70 bpm, was discovered
nly recently. The INDYCE registry provides precise data
n the distribution of these two variables in ambulatory
atients with stable CAD managed routinely by cardiolo-
ists.
Our results are particularly interesting. Indeed, while
he systolic left ventricular function of these patients with
table CAD was generally good (mean LVEF 56.1± 11.8%),
VEF was less than 50% in 29.4% of patients and less
han 40% in 9.6% of patients. It is noteworthy that 70.3%
f the patients with severe left ventricular dysfunction
LVEF < 40%) were free of angina and that 14.1% were com-
letely asymptomatic. This conﬁrms that changes in systolic
eft ventricular function can proceed silently in this set-
ing, and supports the use of regular echocardiographic
onitoring, although the optimal interval remains to be
etermined.
l
o
7
vManagement of our patients complied largely with con-
emporary guidelines, especially with respect to drug
herapy; in particular, nearly three-quarter of patients were
eceiving beta-blockers — a higher proportion than in the
uro Heart Survey (67%) [7] or in the recent LHYCORNE study
62%) [21]. Moreover the mean beta-blocker dose was supe-
ior to that observed in the last French survey focusing on
his topic, where it was close to 50% of the theoretical dose
22].
Closer examination of the data shows that there is
till room for improvement. Indeed, management could
e considered optimal in only one-quarter of cases, being
ased on a beta-blocker, an angiotensin-converting enzyme
nhibitor/angiotensin receptor blocker, a statin and an
ntiplatelet drug, with good control of arterial pressure and
R less than 70 bpm.
Interestingly, three potentially reversible factors wereinked independently to the presence of symptoms, namely
besity, lack of physical exercise and HR greater or equal to
0 bpm. These variables may be suitable targets for inter-
ention, rather than serving merely as gravity signs. Indeed,
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exercise and weight loss are both associated with better out-
come [20], and the analysis of the BEAUTIFUL study [15]
suggests that slowing of HR reduces the risk of myocardial
infarction, especially in patients with angina [23].
Limitations
The main weakness of the INDYCE registry is that
the echocardiographic results were not centralized for
reanalysis. However, differences between LVEF values
determined in a core laboratory and in individual inves-
tigating centres are usually minimal [24]; moreover, in
real life, clinical decisions are taken without any central-
ization of echocardiographic ﬁndings. Finally, as INDYCE
is a registry, it was not possible to evaluate treatment
efﬁcacy: for instance, the correlation between adminis-
tration of beta-blockers, angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers and anti-ischaemic
therapy and the presence of symptoms (Table 3) should not
be misunderstood — these treatments are given because of
the existence of symptoms, they do not worsen them.
Conclusion
LVEF is generally preserved in stable CAD patients. However,
changes in systolic left ventricular function can proceed
silently in this setting. This supports the use of regular
echocardiographic monitoring, although the optimal inter-
val remains to be determined. Three potentially reversible
factors (HR≥ 70 bpm, being overweight and sedentariness)
are linked independently to the presence of symptoms.
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